共 50 条
Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella Typhimurium
被引:34
|作者:
Bargieri, Daniel Y.
[1
,2
]
Leite, Juliana A.
[3
]
Lopes, Stefanie C. P.
[3
]
Sbrogio-Almeida, Maria Elisabete
[4
]
Braga, Catarina J. M.
[5
]
Ferreira, Luis C. S.
[5
]
Soares, Irene S.
[6
]
Costa, Fabio T. M.
[3
]
Rodrigues, Mauricio M.
[1
,2
]
机构:
[1] Univ Fed Sao Paulo, CINTERGEN, Escola Paulista Med, BR-04044010 Sao Paulo, Brazil
[2] Univ Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Imunol & Parasitol, BR-04044010 Sao Paulo, Brazil
[3] Univ Estadual Campinas, Inst Biol, Dept Genet Evolucao & Bioagentes, BR-13083970 Campinas, SP, Brazil
[4] Lab Ctr Biotecnol, Inst Butantan, BR-05503900 Sao Paulo, Brazil
[5] Univ Sao Paulo, Dept Microbiol, Inst Ciencias Biomed, BR-05508900 Sao Paulo, Brazil
[6] Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, BR-05508900 Sao Paulo, Brazil
来源:
基金:
巴西圣保罗研究基金会;
关键词:
P;
falciparum;
Vaccine;
Flagellin;
TLR5;
MALARIA VACCINE;
BACTERIAL FLAGELLIN;
ADJUVANT ACTIVITY;
INFLUENZA VACCINE;
AOTUS-NANCYMAI;
EFFICACY;
ANTIBODIES;
CHALLENGE;
RECEPTOR;
MICE;
D O I:
10.1016/j.vaccine.2010.02.004
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
In a recent study, we demonstrated the immunogenic properties of a new malaria vaccine polypeptide based on a 19 kDa C-terminal fragment of the merozoite surface protein-1 (MSP1(19)) from Plasmodium vivax and an innate immunity agonist, the Salmonella enterica serovar Typhimurium flagellin (FliC). Herein, we tested whether the same strategy, based on the MSP1(19) component of the deadly malaria parasite Plasmodium falciparum, could also generate a fusion polypeptide with enhanced immunogenicity. The His(6)FliC-MSP1(19) fusion protein was expressed from a recombinant Escherichia coli and showed preserved in vitro TLR5-binding activity. In contrast to animals injected with His(6)MSP1(19), mice subcutaneously immunised with the recombinant His6FliC-MSP1(19) developed strong MSP1(19)-specific systemic antibody responses with a prevailing IgG1 subclass. Incorporation of other adjuvants, such as CpG ODN 1826, complete and incomplete Freund's adjuvants or Quil-A, improved the IgG responses after the second, but not the third, immunising dose. It also resulted in a more balanced IgG subclass response, as evaluated by the IgG1/IgG2c ratio, and higher cell-mediated immune response, as determined by the detection of antigen-specific interferon-gamma secretion by immune spleen cells. MSP19-specific antibodies recognised not only the recombinant protein, but also the native protein expressed on the surface of P. falciparum parasites. Finally, sera from rabbits immunised with the fusion protein alone inhibited the in vitro growth of three different P. falciparum strains. In summary, these results extend our previous observations and further demonstrate that fusion of the innate immunity agonist FliC to Plasmodium antigens is a promising alternative to improve their immunogenicity. (c) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2818 / 2826
页数:9
相关论文